NCT07556120尚未招募1 期
An Exploratory Study to Evaluate Safety, Tolerability and Preliminary Efficacy of HN2301 in Patients With Generalized Myasthenia Gravis
Shenzhen MagicRNA Biotechnology Co., Ltd1 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2026年12月31日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Incidence of treatment-emergent adverse events (TEAEs)
研究概览
简要总结
This is an open label, single arm study, to evaluate safety, tolerability and preliminary efficacy of HN2301 in patients with Generalized Myasthenia Gravis.
详细描述
This study consists of a screening period of up to 4 weeks, a treatment period, and a follow-up period of 1 year.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age: 18-80 years, no gender restriction;
- •Confirmed diagnosis of generalized myasthenia gravis (MG) with positive AchR or MuSK antibodies, meeting at least one of the following conditions#(1) Repetitive nerve stimulation suggesting neuromuscular transmission defect; (2) Positive response to neostigmine test; (3) Clinically judged improvement of --MG symptoms after oral cholinesterase inhibitor therapy;
- •Clinical classification of MG according to MGFA types IIa-IVb (including IIa, IIb, IIIa, IIIb, IVa, IVb);
- •Baseline MG-ADL score ≥6, ocular-related score <50%;
- •Poor response and/or lack of efficacy under standard therapies;
- •Minimum life expectancy > 12 weeks;
- •Adequate bone marrow, coagulation, cardiopulmonary, liver, and renal function.
排除标准
- •Subjects positive for hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb) with detectable or quantifiable HBV DNA, positive for hepatitis C antibody (HCV Ab) with detectable or quantifiable HCV RNA, positive for HIV antibody, positive CMV DNA, or CMV DNA above the lower limit of detection; positive for syphilis antigen or antibody;
- •Presence of other uncontrolled active infections;
- •History of major organ transplantation (e.g., heart, lung, liver, kidney) or bone marrow/hematopoietic stem cell transplantation;
- •Pregnant or breastfeeding women;
- •Receipt of any mRNA-LNP products or other LNP-based drugs within the past two years;
- •History of any of the following cardiovascular conditions within 6 months prior to screening: New York Heart Association (NYHA) Class III or IV heart failure, myocardial infarction, unstable angina, uncontrolled or symptomatic atrial arrhythmias, any ventricular arrhythmias, or other clinically significant cardiac disease;
- •History of ≥Grade 2 bleeding events within 30 days prior to screening, or requiring long-term continuous anticoagulation therapy (e.g., warfarin, low molecular weight heparin, Xa factor inhibitors);
- •History of live vaccination within 30 days prior to screening;
- •Severe central nervous system diseases or pathological changes, including but not limited to: cerebrovascular accident, aneurysm, epilepsy, seizures/convulsions, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disorders, organic brain syndromes, or psychosis;
- •History of asthma or severe allergies;
- •Patients combined with other malignant tumors;
- •Any condition that, in the investigator's opinion, may increase the patient's risk or interfere with study assessments.
研究组 & 干预措施
HN2301 treatment group
Experimental
Participants will receive HN2301 Injection at the specified dose level and on the specified study days.
干预措施: HN2301 injection (Drug)
结局指标
主要结局
Incidence of treatment-emergent adverse events (TEAEs)
时间窗: Up to 3 months
Incidence, nature, and severity of treatment-emergent adverse events, assessed according to the study protocol and applicable toxicity grading criteria.
次要结局
- in vivo CAR T cell production(Up to14 days)
- Absolute B-cell count in peripheral blood(Up to 12 months)
- Changes from baseline in Myasthenia Gravis Activities of Daily Living(MG-ADL) score(Up to 12 months])
- Changes from baseline in Myasthenia Gravis Composite (MGC) score(Up to 12 months)
- Changes from baseline in Quantitative Myasthenia Gravis (QMG) score(Up to 12 months])
- Changes from baseline in revised Myasthenia Gravis Quality of Life-15 score (MG-QOL15r)(Up to 12 months)
- Changes in acetylcholine receptor (AchR) antibody levels after treatment(Up to 12 months)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)NCT07413835The Affiliated Hospital of Xuzhou Medical University6
尚未招募
1 期
Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune DiseasesAutoimmune DiseaseSystemic Sclerosis (SSc)Systemic Lupus ErythematosusNCT07523282Shenzhen MagicRNA Biotechnology Co., Ltd12
已完成
不适用
A Clinical Study to determine the safety and Efficacy of an oral probiotic supplementation in the management of Irritable Bowel Syndrome with protein digestion.CTRI/2024/11/076363Meteoric Biopharmaceuticals Pvt. Ltd.18
尚未招募
不适用
A Study to Investigate the Safety and Effectiveness of the Technolas® TENEO 317 Model 2 Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Myopia or Myopic AstigmatismNCT07377474Bausch & Lomb Incorporated32
尚未招募
1 期
Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic MalignanciesNCT07485504Tcelltech Inc.15